List view / Grid view

ViiV Healthcare

 

Global dual-drug trial aims to advance HIV treatment

16 August 2016 | By ViiV Healthcare

ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…

BMS divests its HIV R&D assets to ViiV Healthcare

18 December 2015 | By Victoria White

ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...